MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock upon...
$98,968K
Proceeds from borrowing
of the term loan,...
$24,700K
Proceeds from issuance of
common stock under the...
$16,940K
Proceeds from exercise of
common stock options
$1,987K
Proceeds from maturities
of...
$405,701K
Proceeds from sale of
property and equipment
$70K
Net cash provided by
financing activities
$141,168K
Net cash provided by
(used in) investing...
$40,015K
Canceled cashflow
$1,427K
Canceled cashflow
$365,756K
Net increase in cash
and cash...
$27,471K
Canceled cashflow
$153,712K
Principal paid on finance
lease liabilities
$808K
Payments for common stock
issuance offering costs
$475K
Taxes paid related to
net share...
$144K
Stock-based compensation
$10,080K
Accrued compensation
$5,107K
Non-cash lease expense
$2,900K
Depreciation and
amortization expense
$1,799K
Prepaid expense and
other current assets
-$893K
Impairment of capitalized
software
$648K
Accounts payable
$543K
Non-cash interest
expense
$72K
Loss on disposal of
property and equipment
-$60K
Purchases of
available-for-sale marketable...
$364,623K
Internal-use software
development costs
$1,128K
Purchases of property and
equipment
$5K
Net cash used in
operating activities
-$153,712K
Canceled cashflow
$22,102K
Net loss
-$161,307K
Accretion of discounts on
available-for-sale marketable...
$6,888K
Operating lease liability
-$3,339K
Accrued license expense
- related party
-$2,500K
Other non-current
assets
$980K
Other accrued
expenses and current...
-$800K
Back
Back
Cash Flow
source: myfinsight.com
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)